Search

Displaying results 1381 - 1390 of 5758 in total
  1. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from DB12604. The structure of plazomicin was established via appending hydroxylaminobutyric acid to DB12604 at position 1 and...

  2. Drug

    PF-04691502

    go.drugbank.com/drugs/DB11974
    Investigational

    PF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).

  3. Drug

    Enadenotucirev

    go.drugbank.com/drugs/DB14873
    Investigational

    Enadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors).

  4. Drug

    Uteroglobin

    go.drugbank.com/drugs/DB14880
    Investigational

    Uteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).

  5. Drug

    PF-00489791

    go.drugbank.com/drugs/DB11736
    Investigational

    PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.

  6. Drug

    Ciforadenant

    go.drugbank.com/drugs/DB16125
    Investigational

    Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).

  7. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: PR Natal 430, PR Natal 400
  8. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  9. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam has a monoisotopic molecular weight of 518.05 Da. … Ancremonam is under investigation in clinical trial NCT03377426 (LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)).

  10. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall . It is used in the treatment of multidrug-resistant and extensively dru...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates